Developing membrane-derived nanocarriers for ex vivo therapy of homologous breast cancer cells
| Autor: | Anil Parsram Bidkar, Muktashree Saha, Siddhartha Sankar Ghosh |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
chemistry.chemical_classification
Reactive oxygen species media_common.quotation_subject Biomedical Engineering Medicine (miscellaneous) Bioengineering Development Cell membrane medicine.anatomical_structure Targeted drug delivery chemistry Apoptosis medicine Cancer research General Materials Science Doxorubicin Nanocarriers Internalization Ex vivo medicine.drug media_common |
| Zdroj: | Nanomedicine. 16:1843-1856 |
| ISSN: | 1748-6963 1743-5889 |
| DOI: | 10.2217/nnm-2021-0153 |
| Popis: | Aim: The primary aim of this study was to develop biomimetic nanocarriers for specific homologous targeting of the anticancer drugs ammonium pyrrolidine dithiocarbamate (PDTC) and doxorubicin. Methods: Membranous nanovesicles were synthesized from a breast cancer cell line (MCF7) by syringe extrusion process and were loaded with PDTC and doxorubicin. Besides their abilities for self-homing, the drug-loaded nanovesicles showed anti-cell proliferative effects via the generation of reactive oxygen species. Results: The nanovesicles demonstrated efficient internalization via homologous targeting. Delivery of PDTC showed a higher killing effect for homologous cell targeting than other cell types. Experimental results demonstrated increased antiproliferative potency of PDTC, which induced apoptosis via reactive oxygen species generation. Conclusion: The developed membrane-derived nanocarrier is an attractive biocompatible system for ex vivo targeted drug delivery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|